PacBio to collaborate with National Cancer Centre of Singapore on cancer profiling

Dna Sequencing Data Analysis Social

Sequencing firm PacBio has signed a research collaboration agreement with the National Cancer Centre of Singapore to advance cancer research by profiling the cancer types that are prevalent in Asia.

The collaboration will use PacBio's research use only Onso short-read sequencing system and Kinnex long-read sequencing kit, with a particular focus on single-cell RNA sequencing. Using both Onso and Revio is intended to ensure an in-depth, comprehensive analysis of the cancer genome, PacBio said in a statement. Moreover, with Revio's long-read sequencing capabilities, the collaboration will allow researchers to analyze transcript isoforms and genetic variants at the single-cell level, according to the company.

PacBio's authorized channel partner in Asia, DKSH, has installed the Onso platform at the NCCS' Cancer Discovery Hub. The Onso platform will enable researchers to detect clinically relevant mutations across various cancer types, such as gastrointestinal stromal tumors, PacBio explained.

The partners said that they anticipate the findings from the collaboration to benefit not only Singapore but also the larger cancer research community in Asia.

"We are excited to collaborate with PacBio on this initiative which combines the power of short-read and long-read sequencing, allowing us to delve deeper into the genomic complexities of cancers prevalent in Asia," Jason Chan, director of the Cancer Discovery Hub at NCCS, said. "The ultimate aim is to improve tailored diagnostic and treatment options for our patients."

Page 1 of 2
Next Page